CUBEBIO Partners with Mountain Crest V for Public Listing
Mountain Crest Acquisition Corp. V, a Delaware-based special purpose acquisition company whose common stock is traded on The Nasdaq Stock Market under the symbol "MCAG," has recently made an exciting announcement alongside CUBEBIO Co., Ltd., a company established under Korean law. CUBEBIO has pioneered groundbreaking technology that facilitates early cancer diagnosis through urine analysis, with the goal of significantly enhancing the accessibility of cancer screening.
Definitive Business Combination Agreement Announced
The two companies have finalized a definitive business combination agreement, paving the way for CUBEBIO to become publicly listed on The Nasdaq Stock Market. This transaction will enable CUBEBIO to benefit from Mountain Crest V’s expertise while furthering its business objectives. The upcoming business combination includes two major transactions that will strengthen the collaboration between the two firms.
Details of the Transaction
According to the agreement, CHL SPAC Merger Sub, Inc., a corporation to be established in Delaware, will merge with Mountain Crest V, which will continue as the surviving entity. After this merger, shareholders of Mountain Crest V will exchange their shares for Ordinary Shares of CubeBio Holdings Limited, a new entity incorporated in the Cayman Islands. Simultaneously, all shareholders of CUBEBIO will transfer their shares to a Korean subsidiary in return for shares in the new public company. The pre-transaction equity valuation is set at $375 million, and the plan includes potential earn-out payments tied to CUBEBIO’s future financial performance.
Market Potential and Future Growth
Dr. Suying Liu, Chairman and CEO of Mountain Crest V, has expressed excitement about CUBEBIO's innovative cancer diagnostic technology. He believes that CUBEBIO is well-positioned to seize substantial growth opportunities within the healthcare sector. Through this merger, both companies anticipate improved operational efficiencies and a stronger market presence.
CUBEBIO's Innovative Technologies
CUBEBIO specializes in in-vitro diagnostics, employing non-invasive techniques to detect cancer early by analyzing metabolites in urine. The company holds numerous patents related to cancer diagnostics and has successfully developed various diagnostic kits, including CEED-PG/PGS and CEED-NOVUS, aimed at serving both local and international markets.
Recent Contracts and Global Plans
Recently, CUBEBIO secured a significant contract valued at approximately $14.5 million with Taiwan Biotech Co., Ltd. to supply cancer screening products. This agreement allows CUBEBIO to extend its reach into Taiwan, Vietnam, and Malaysia. Regulatory approval in these regions is pending, and revenue generation is anticipated in the near future. Additionally, the company is exploring opportunities to distribute its products in the United States and Japan, reinforcing its ambition to become a global leader in cancer diagnostics.
Expertise and Guidance
Global Fund LLC has been appointed as an advisory firm, specializing in SPAC transactions, to support CUBEBIO throughout the business combination process. Mountain Crest V has engaged legal counsel from Loeb & Loeb LLP, while CUBEBIO's interests are being managed by Nelson Mullins Riley & Scarborough LLP, ensuring both companies effectively navigate the regulatory landscape.
Anticipation for Completion
Both firms are optimistic about completing the business combination by early 2025. Eun-jong Choi, CEO of CUBEBIO, highlighted their commitment to expanding CUBEBIO's operations globally and enhancing its market value through this partnership. The management teams are diligently working to realize this successful collaboration.
Frequently Asked Questions
What is the proposed business combination about?
The proposed business combination involves CUBEBIO merging with Mountain Crest V, with the aim of making CUBEBIO a publicly listed company on The Nasdaq.
What technology does CUBEBIO specialize in?
CUBEBIO specializes in in-vitro diagnostics, utilizing urine analysis to detect cancer at an early stage, thereby improving accessibility to cancer screening.
When is the business combination expected to close?
The business combination is anticipated to close in the first quarter of 2025.
Who are the legal counsels involved in the merger?
Mountain Crest V is represented by Loeb & Loeb LLP, while CUBEBIO is represented by Nelson Mullins Riley & Scarborough LLP.
What is included in CUBEBIO's future plans?
CUBEBIO aims to expand its product offerings in international markets, including the U.S. and Japan, while continuing to innovate its cancer diagnostic technologies.
